No. PAR-25-336 · National Institutes of Health
Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
Not reimbursement-only
“Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.” — From the announcement
- Award range
- Not specified
- Expected awards
- Not specified
- Application deadline
- Nov 15, 2027
- Posted
- Dec 16, 2024
- Last verified
- 8 days ago
At a glance
AI summaryThis program funds translational research on nanotechnology-based cancer interventions, including combination therapy, immunotherapy, and imaging or diagnostics. Eligible applicants include a wide range of U.S. organizations such as nonprofits, universities, governments, for-profits, small businesses, and tribal organizations; foreign organizations are not eligible, though foreign components of U.S. organizations are allowed. Awards are limited to $475,000 in direct costs per year for up to 4 years, and the number of awards depends on NIH appropriations and the quality of applications. No cost sharing is required, and clinical trials are not allowed.
AI-generated summary — verify against the announcement
What it funds
Official description from grants.gov
Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments
Program history
USASpending.govAssistance listing 93.395 · Cancer Treatment Research
Real awards this federal program has made — the whole assistance listing (93.395), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 316 | $565,152 | $413,691 – $664,926 |
| FY 2025 | 435 | $677,787 | $402,400 – $1,233,798 |
| FY 2024 | 488 | $1,140,586 | $408,966 – $1,897,871 |
| FY 2023 | 522 | — | — |
| FY 2022 | 519 | — | — |
| FY 2021 | 517 | — | — |
Dollar figures are based on the 1,000 most recent awards we store, not all 2,797 — award counts are complete.
- THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER $6,902,371 · FY 2024
- VIRGINIA COMMONWEALTH UNIVERSITY $5,325,147 · FY 2024
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY $4,597,865 · FY 2024
- PRIVO TECHNOLOGIES, INC. $4,499,992 · FY 2024
- FRED HUTCHINSON CANCER CENTER $4,234,248 · FY 2025
Source: USASpending.gov · refreshed Aug 18, 2026